Announcements Trials

Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Cardiotoxicity 5 Neoplasms 3 Breast Neoplasms 3 Heart Failure 2 Dyslipidemias 2 Cardiovascular Diseases 2 Ventricular Dysfunction, Left 1 Thoracic Neoplasms 1 Smoking 1 Pulmonary Disease, Chronic Obstructive 1 Overweight 1 Obesity 1 Noncommunicable Diseases 1 Metabolic Syndrome 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hypokinesia 1 Hypertension 1 Hyperglycemia 1 Diabetes Mellitus 1 Coronary Disease 1 Cerebrovascular Disorders 1 Central Nervous System Neoplasms 1 Cardiomyopathies 1 Atrial Fibrillation 1 Asthma 1 Alcohol Drinking 1

Interventions

Blood Specimen Collection 14 Nivolumab 13 Ipilimumab 12 pembrolizumab 11 trametinib 9 Surveys and Questionnaires 9 Gene Expression Profiling 9 dabrafenib 8 Biopsy 6 Specimen Handling 5 Immunotherapy 5 Immunohistochemistry 5 Amplified Fragment Length Polymorphism Analysis 4 encorafenib 3 binimetinib 3 atezolizumab 3 Restraint, Physical 3 Quality of Life 3 Polymerase Chain Reaction 3 Introns 3 Flow Cytometry 3 Drug Therapy 3 Data Collection 3 tremelimumab 2 pimonidazole 2 cobimetinib 2 aldesleukin 2 Watchful Waiting 2 Vemurafenib 2 Therapeutics 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Melanoma × Electrocardiography × Clear all

NCT06605833 2025-10-01

CARD-IO

Royal Marsden NHS Foundation Trust

Enrolling by invitation

Melanoma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡